Tags Archive Navigation
icon
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
-
Media ReleaseNovartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
-
Media ReleaseNovartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
-
Media ReleaseNovartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Media ReleaseNovartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
-
Media ReleaseNovartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
-
Media ReleaseNovartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14
-
Media ReleaseNovartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
-
Media ReleaseNovartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
-
Media ReleaseNovartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- › Next page